Jeremy J. Kodanko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jeremy J. Kodanko has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Turro
The Ohio State University
21 shared publications Izabela Podgorski
Barbara Ann Karmanos Cancer Institute
11 shared publicationsClaudia Turro
Department of Chemistry and Biochemistry The Ohio State University Columbus Ohio 43210 USA
9 shared publicationsSayak Gupta
Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, Michigan 48202, United States
8 shared publicationsMackenzie K. Herroon
Department of Pharmacology, School of Medicine, Wayne State University
7 shared publicationsAo Li
Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, Michigan 48202, United States
6 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (27) , 11745-11750
Foamable Protein-Ligand Conjugates: A Sustainable Approach to Rare-Earth Metal Harvesting and Separation by Ion Flotation
- 29 June 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (27) , 11745-11750
Open AccessFoamable Protein-Ligand Conjugates: A Sustainable Approach to Rare-Earth Metal Harvesting and Separation by Ion Flotation
- Open Access
- 29 April 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (19) , 29202-29210
Beyond IC 50 : Reframing Microcystin Potency against Protein Phosphatase 2A by Defining Two-Step Irreversible Inhibition Kinetics
Microcystins (MCs) are among the most potent natural inhibitors of serine/threonine protein phosphatases, yet their toxicity is typically assessed using IC50 values that obscure the underlying kinetics and mechanism of enzyme inactivation. Here, we present a comprehensive kinetic analysis of protein phosphatase 2A (PP2A) inhibition by a panel of structurally diverse MC congeners, including MC-LR, MC-LA, MC-LW, MC-RR, [d-Asp3] MC-LR, and the noncovalent control [d-Asp3][Dhb7] MC-RR. Using an established PP2A inhibition assay method and modeling software to determine Ki, kinact, and kinact/Ki, we resolved reversible binding from covalent inactivation to characterize the two-step inhibition mechanism. All covalently competent MCs bind PP2A with picomolar affinity (Ki ≈ 3–11 pM) and undergo slow but tightly constrained covalent modification of Cys269 (kinact ≈ 3–5 × 10–4 s–1), yielding near–diffusion-limited inactivation efficiencies (kinact/Ki ≈ 107–108 M–1 s–1). Structural variation among congeners primarily modulates binding equilibrium and the fraction of complexes that achieve a productive geometry for covalent bond formation, while the irreversible inactivation step remains relatively similar. Notably, [d-Asp3][Dhb7] MC-RR binds PP2A with picomolar affinity despite lacking a highly reactive electrophile, demonstrating that high-affinity engagement is mechanistically separable from covalent inactivation. These results reveal that MC potency is driven by exceptionally tight and persistent PP2A binding rather than fast reactivity, providing a kinetic framework that links molecular structure to sustained phosphatase inactivation and real-world toxicity during harmful algal bloom exposure.
- 29 April 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (19) , 29202-29210
Open AccessBeyond IC 50 : Reframing Microcystin Potency against Protein Phosphatase 2A by Defining Two-Step Irreversible Inhibition Kinetics
Microcystins (MCs) are among the most potent natural inhibitors of serine/threonine protein phosphatases, yet their toxicity is typically assessed using IC50 values that obscure the underlying kinetics and mechanism of enzyme inactivation. Here, we present a comprehensive kinetic analysis of protein phosphatase 2A (PP2A) inhibition by a panel of structurally diverse MC congeners, including MC-LR, MC-LA, MC-LW, MC-RR, [d-Asp3] MC-LR, and the noncovalent control [d-Asp3][Dhb7] MC-RR. Using an established PP2A inhibition assay method and modeling software to determine Ki, kinact, and kinact/Ki, we resolved reversible binding from covalent inactivation to characterize the two-step inhibition mechanism. All covalently competent MCs bind PP2A with picomolar affinity (Ki ≈ 3–11 pM) and undergo slow but tightly constrained covalent modification of Cys269 (kinact ≈ 3–5 × 10–4 s–1), yielding near–diffusion-limited inactivation efficiencies (kinact/Ki ≈ 107–108 M–1 s–1). Structural variation among congeners primarily modulates binding equilibrium and the fraction of complexes that achieve a productive geometry for covalent bond formation, while the irreversible inactivation step remains relatively similar. Notably, [d-Asp3][Dhb7] MC-RR binds PP2A with picomolar affinity despite lacking a highly reactive electrophile, demonstrating that high-affinity engagement is mechanistically separable from covalent inactivation. These results reveal that MC potency is driven by exceptionally tight and persistent PP2A binding rather than fast reactivity, providing a kinetic framework that links molecular structure to sustained phosphatase inactivation and real-world toxicity during harmful algal bloom exposure.
- Open Access
- 21 January 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (2) , 210-223
Structure–Activity Relationships of Anabaenopeptins as Carboxypeptidase and Phosphatase Inhibitors
Anabaenopeptins are a family of cyanobacterial cyclic peptides that display potent enzyme inhibition, particularly against carboxypeptidases A and B, as well as the serine/threonine phosphatases PP1 and PP2A. Defined by a 19-membered macrocyclic ring and a ureido-linked exocyclic amino acid, these compounds vary considerably in their amino acid composition, influencing both potency and selectivity. This review compiles published IC50 values for natural and synthetic anabaenopeptins, organizing them by enzyme target, and highlighting recurring structural motifs that drive inhibitory activity. Through this comparative analysis, we identify emerging trends in structure-activity relationships and underscore gaps in assay standardization and structural validation. These insights provide a critical foundation for advancing the biological evaluation of anabaenopeptins as environmental contaminants, mechanistic probes, and candidate scaffolds for therapeutic development.
- 21 January 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (2) , 210-223
Open AccessStructure–Activity Relationships of Anabaenopeptins as Carboxypeptidase and Phosphatase Inhibitors
Anabaenopeptins are a family of cyanobacterial cyclic peptides that display potent enzyme inhibition, particularly against carboxypeptidases A and B, as well as the serine/threonine phosphatases PP1 and PP2A. Defined by a 19-membered macrocyclic ring and a ureido-linked exocyclic amino acid, these compounds vary considerably in their amino acid composition, influencing both potency and selectivity. This review compiles published IC50 values for natural and synthetic anabaenopeptins, organizing them by enzyme target, and highlighting recurring structural motifs that drive inhibitory activity. Through this comparative analysis, we identify emerging trends in structure-activity relationships and underscore gaps in assay standardization and structural validation. These insights provide a critical foundation for advancing the biological evaluation of anabaenopeptins as environmental contaminants, mechanistic probes, and candidate scaffolds for therapeutic development.
- 28 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (1) , 902-912
Leveraging Intramolecular π-Stacking in Ru(II)-Pyridine Complexes to Induce Photoinduced Ligand Dissociation
[Ru(tpy)(L)(py)]2+ (tpy = 2,2;6'2″-terpyridine; py = pyridine), where L represents 1,10-phenanthroline (1; phen), 2-phenyl-1,10-phenanthroline (2; phenyl-phen), and 2-(1'-pyrenyl)-1,10-phenanthroline (3; pyrenyl-phen), were synthesized and characterized by 1D and 2D 1H NMR and through X-ray crystallography. These methods show that 2 and 3 exhibit intramolecular, interligand π-stacking between the phenyl and pyrenyl groups of the substituted phen ligands in 2 and 3, respectively, and the tpy ligand in each complex. DFT calculations show that the deviation from octahedral geometry around the metal in 2 and 3 leads to a lower energy eg-type orbital set with Ru-py(σ*) character, making the dissociative metal-centered (MC) excited state(s) more accessible from the metal-to-ligand charge transfer (MLCT) states in these complexes relative to 1. The lifetimes of the lowest energy Ru→tpy 3MLCT excited states in 2 and 3 are shorter than that of 1, consistent with the more facile 3MLCT deactivation through the 3MC state(s) in 2 and 3 as compared to 1. Complexes 2 and 3 undergo pyridine ligand exchange with a Cl- ion in CH2Cl2 with quantum yields, Φ450, of 0.024(2) and Φ450 = 0.019(3), respectively (λirr = 450 nm), representing a > 100-fold increase as compared to that of 1, Φ450 < 10-4. The increase in photoinduced ligand exchange in 2 and 3 is attributed to the greater population of the dissociative 3MC state(s) in these complexes. This represents the first demonstration that intramolecular π-stacking in Ru(II) complexes can be used to enhance ligand release upon irradiation, highlighting a new method to achieve more efficient delivery of pyridine-containing drugs for photochemotherapy.
- 28 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (1) , 902-912
Leveraging Intramolecular π-Stacking in Ru(II)-Pyridine Complexes to Induce Photoinduced Ligand Dissociation
[Ru(tpy)(L)(py)]2+ (tpy = 2,2;6'2″-terpyridine; py = pyridine), where L represents 1,10-phenanthroline (1; phen), 2-phenyl-1,10-phenanthroline (2; phenyl-phen), and 2-(1'-pyrenyl)-1,10-phenanthroline (3; pyrenyl-phen), were synthesized and characterized by 1D and 2D 1H NMR and through X-ray crystallography. These methods show that 2 and 3 exhibit intramolecular, interligand π-stacking between the phenyl and pyrenyl groups of the substituted phen ligands in 2 and 3, respectively, and the tpy ligand in each complex. DFT calculations show that the deviation from octahedral geometry around the metal in 2 and 3 leads to a lower energy eg-type orbital set with Ru-py(σ*) character, making the dissociative metal-centered (MC) excited state(s) more accessible from the metal-to-ligand charge transfer (MLCT) states in these complexes relative to 1. The lifetimes of the lowest energy Ru→tpy 3MLCT excited states in 2 and 3 are shorter than that of 1, consistent with the more facile 3MLCT deactivation through the 3MC state(s) in 2 and 3 as compared to 1. Complexes 2 and 3 undergo pyridine ligand exchange with a Cl- ion in CH2Cl2 with quantum yields, Φ450, of 0.024(2) and Φ450 = 0.019(3), respectively (λirr = 450 nm), representing a > 100-fold increase as compared to that of 1, Φ450 < 10-4. The increase in photoinduced ligand exchange in 2 and 3 is attributed to the greater population of the dissociative 3MC state(s) in these complexes. This represents the first demonstration that intramolecular π-stacking in Ru(II) complexes can be used to enhance ligand release upon irradiation, highlighting a new method to achieve more efficient delivery of pyridine-containing drugs for photochemotherapy.
- 18 September 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (39) , 35198-35202
Cytochrome P450 Induction through the Efficient Photoinduced Release of a Pyridine-Substituted Agent from Ru(II)
We report the first example of using photoinduced ligand release from a Ru(II) complex for light-triggered cytochrome P450 (CYP) induction. CYPs are pivotal enzymes in biosynthesis and drug metabolism, and their induction can be leveraged for therapeutics and biochemical research. We show the activation of a CYP1A1 with visible light through the efficient photorelease of an aryl hydrocarbon receptor (AHR; 1) agonist with a quantum yield, Φ500, of 0.16(1) with λirr = 500 nm in [Ru(tpy)(Me2bpy)(1)]2+ (tpy = 2,2':6',2″-terpyridine, Me2bpy = 6,6'-dimethyl-2,2'-bipyridine). This value is consistent with that previously reported for pyridine (py) exchange in the analogous [Ru(tpy)(Me2bpy)(py)]2+ complex, Φ500 = 0.16(1), which is driven by steric effects. In contrast to [Ru(tpy)(bpy)(py)]2+ (bpy = 2,2'-bipyridine), with Φ500 < 10-4, the ligand photodissociation in [Ru(tpy)(bpy)(1)]2+ proceeds with Φ500 = 0.015(1), at least 2 orders of magnitude more efficiently. Similarly, [Ru(tpy)(biq)(1)]2+ (4; biq = 2,2'-biquinoline) undergoes photoinduced exchange of 1 with CH3CN solvent with Φ500 = 0.064(3), more efficiently than [Ru(tpy)(biq)(py)]2+ with Φ500 = 0.03. Through experiments and calculations, we show the involvement of intraligand charge transfer (ILCT) within the leaving ligand in an unprecedented mechanism for ligand photodissociation from Ru(II). Chemical tools based on these findings hold the promise of advancing research on tissue-specific CYP activity by enabling precise spatiotemporal control. Moreover, these compounds may pave the way for the development of highly specific and light-activated pharmaceuticals that enhance the synergy with existing drugs.
- 18 September 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (39) , 35198-35202
Cytochrome P450 Induction through the Efficient Photoinduced Release of a Pyridine-Substituted Agent from Ru(II)
We report the first example of using photoinduced ligand release from a Ru(II) complex for light-triggered cytochrome P450 (CYP) induction. CYPs are pivotal enzymes in biosynthesis and drug metabolism, and their induction can be leveraged for therapeutics and biochemical research. We show the activation of a CYP1A1 with visible light through the efficient photorelease of an aryl hydrocarbon receptor (AHR; 1) agonist with a quantum yield, Φ500, of 0.16(1) with λirr = 500 nm in [Ru(tpy)(Me2bpy)(1)]2+ (tpy = 2,2':6',2″-terpyridine, Me2bpy = 6,6'-dimethyl-2,2'-bipyridine). This value is consistent with that previously reported for pyridine (py) exchange in the analogous [Ru(tpy)(Me2bpy)(py)]2+ complex, Φ500 = 0.16(1), which is driven by steric effects. In contrast to [Ru(tpy)(bpy)(py)]2+ (bpy = 2,2'-bipyridine), with Φ500 < 10-4, the ligand photodissociation in [Ru(tpy)(bpy)(1)]2+ proceeds with Φ500 = 0.015(1), at least 2 orders of magnitude more efficiently. Similarly, [Ru(tpy)(biq)(1)]2+ (4; biq = 2,2'-biquinoline) undergoes photoinduced exchange of 1 with CH3CN solvent with Φ500 = 0.064(3), more efficiently than [Ru(tpy)(biq)(py)]2+ with Φ500 = 0.03. Through experiments and calculations, we show the involvement of intraligand charge transfer (ILCT) within the leaving ligand in an unprecedented mechanism for ligand photodissociation from Ru(II). Chemical tools based on these findings hold the promise of advancing research on tissue-specific CYP activity by enabling precise spatiotemporal control. Moreover, these compounds may pave the way for the development of highly specific and light-activated pharmaceuticals that enhance the synergy with existing drugs.
- 1 August 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (32) , 11753-11756
A Highly Convergent Synthesis Route for Adda: A Non-Proteinogenic Amino Acid Unit in Cyanobacteria
We report a concise nine-step synthesis of Boc-Adda-OH, a key residue in bioactive cyanobacterial peptides. The route features a regio- and stereoselective intermolecular Heck reaction to form a stable isoxazolidin-5-one, followed by N-O bond cleavage. This efficient, convergent approach offers excellent stereocontrol and functional group tolerance, facilitating access to Adda for natural product synthesis, environmental monitoring, and toxicological studies.
- 1 August 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (32) , 11753-11756
A Highly Convergent Synthesis Route for Adda: A Non-Proteinogenic Amino Acid Unit in Cyanobacteria
We report a concise nine-step synthesis of Boc-Adda-OH, a key residue in bioactive cyanobacterial peptides. The route features a regio- and stereoselective intermolecular Heck reaction to form a stable isoxazolidin-5-one, followed by N-O bond cleavage. This efficient, convergent approach offers excellent stereocontrol and functional group tolerance, facilitating access to Adda for natural product synthesis, environmental monitoring, and toxicological studies.
- Open Access
Structure, Toxicity, Prevalence, and Degradation of Six Understudied Freshwater Cyanopeptides
Anthropogenic influences have increased global warming and eutrophication, escalating the frequency and severity of harmful cyanobacterial blooms (cHABs) in freshwater ecosystems. These blooms release cyanopeptides, a diverse class of bioactive compounds with varying acute and chronic toxicities upon ingestion. To date, research has prioritized acutely toxic cyanopeptides like microcystins. As a result, significantly less is known about other freshwater cyanopeptides. This review highlights six understudied cyanopeptide classes, anabaenopeptins, cyanopeptolins, aeruginosamides, aeruginosins, microginins, and cyclamides, and provides a comprehensive overview of their molecular structures, toxicological profiles, environmental concentrations, and known degradation pathways. Given the potential toxicity, increased environmental abundance, and environmental stability of many cyanopeptides in freshwater sources, further research is needed to understand if degraded cyanopeptides are still biologically active prior to entering drinking water to ensure public health.
Open AccessStructure, Toxicity, Prevalence, and Degradation of Six Understudied Freshwater Cyanopeptides
Anthropogenic influences have increased global warming and eutrophication, escalating the frequency and severity of harmful cyanobacterial blooms (cHABs) in freshwater ecosystems. These blooms release cyanopeptides, a diverse class of bioactive compounds with varying acute and chronic toxicities upon ingestion. To date, research has prioritized acutely toxic cyanopeptides like microcystins. As a result, significantly less is known about other freshwater cyanopeptides. This review highlights six understudied cyanopeptide classes, anabaenopeptins, cyanopeptolins, aeruginosamides, aeruginosins, microginins, and cyclamides, and provides a comprehensive overview of their molecular structures, toxicological profiles, environmental concentrations, and known degradation pathways. Given the potential toxicity, increased environmental abundance, and environmental stability of many cyanopeptides in freshwater sources, further research is needed to understand if degraded cyanopeptides are still biologically active prior to entering drinking water to ensure public health.
- 19 September 2024
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 12 (42) , 15370-15375
Sustainable Protein Conjugates as a Soluble Capture and Release System for Lanthanides
- 19 September 2024
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 12 (42) , 15370-15375
Sustainable Protein Conjugates as a Soluble Capture and Release System for Lanthanides
- 16 September 2024
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 63 (40) , 18509-18518
Mixed Ru(II)–Ir(III) Complexes as Photoactive Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4
Cytochrome P450 3A4 (CYP3A4) is a crucial enzyme in human drug metabolism. To garner photochemical control over the inhibition of CYP3A4, a potent Ir(III)-based inhibitor of CYP3A4 was complexed with two Ru(II)-based photocaging groups. Chemical, photochemical, and biological properties of the photocaged inhibitors were characterized. Importantly, mixed Ru(II)-Ir(III) complexes strongly absorb green light, which facilitates the photochemical release of the Ir(III) inhibitor from the Ru(II) caging fragment [Ru(tpy)(Me2bpy)]2+, where tpy = 2,2':6',2″-terpyridine and Me2bpy = 6,6'-dimethyl-2,2'-bipyridine. Emission turn on, type II heme binding, and more potent inhibition under light vs dark conditions were observed. The study also demonstrated that a Ru(II)-Ir(III) conjugate can be photoactivated to exert cytotoxic effects on MCF-7 breast cancer cells upon green light exposure. Additionally, a synthesized analogue with one [Ru(TPA)]2+ fragment (TPA = tris(pyridin-2-ylmethyl)amine) and two Ir(III) centers, although resistant to photochemical release, showed strong inhibition of CYP3A4 both in purified form and in CYP3A4-overexpressing HepG2 cells, with nanomolar potency. These mixed Ru(II)-Ir(III) compounds can permeate cell membranes and inhibit CYP3A4, presenting a new class of bioactive compounds.
- 16 September 2024
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 63 (40) , 18509-18518
Mixed Ru(II)–Ir(III) Complexes as Photoactive Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4
Cytochrome P450 3A4 (CYP3A4) is a crucial enzyme in human drug metabolism. To garner photochemical control over the inhibition of CYP3A4, a potent Ir(III)-based inhibitor of CYP3A4 was complexed with two Ru(II)-based photocaging groups. Chemical, photochemical, and biological properties of the photocaged inhibitors were characterized. Importantly, mixed Ru(II)-Ir(III) complexes strongly absorb green light, which facilitates the photochemical release of the Ir(III) inhibitor from the Ru(II) caging fragment [Ru(tpy)(Me2bpy)]2+, where tpy = 2,2':6',2″-terpyridine and Me2bpy = 6,6'-dimethyl-2,2'-bipyridine. Emission turn on, type II heme binding, and more potent inhibition under light vs dark conditions were observed. The study also demonstrated that a Ru(II)-Ir(III) conjugate can be photoactivated to exert cytotoxic effects on MCF-7 breast cancer cells upon green light exposure. Additionally, a synthesized analogue with one [Ru(TPA)]2+ fragment (TPA = tris(pyridin-2-ylmethyl)amine) and two Ir(III) centers, although resistant to photochemical release, showed strong inhibition of CYP3A4 both in purified form and in CYP3A4-overexpressing HepG2 cells, with nanomolar potency. These mixed Ru(II)-Ir(III) compounds can permeate cell membranes and inhibit CYP3A4, presenting a new class of bioactive compounds.
- Open Access
Ru(II)-Photoactive Agents for Targeting ER Stress and Immunogenic Cell Death
Immunotherapy has emerged as a promising avenue for cancer treatment by bolstering the immune system’s ability to recognize and attack cancer cells. Photodynamic therapy shows potential in enhancing antitumor immunity, though the mechanisms behind its success are not fully understood. In this manuscript, we investigate two previously reported green light activated PCT/PDT agents where compound 2 - [Ru(tpy)(Me2bpy)( 3 )] 2+ , (tpy = 2,2’:6’,2’’- terpyridine, Me2bpy = 6,6’-dimethyl-2,2’-bipyridine, 3 = pyridyl-BODIPY-I2,) - shows remarkable photoselectivity in assays containing both 2D cancer cells and 3D cocultures containing BALB/c macrophages and 4T1 murine breast cancer cells. Through flow cytometry and protein analysis, we found complex 2 displays superior evidence of induced endoplasmic reticulum (ER) stress markers and indicators of immunogenic cell death (ICD) compared to its ligand 3 , despite its weaker photoselectivity. Most importantly, these results were supported by in vivo studies where 2 produced anti-tumor immunity against the 4T1 tumor model in BALB/c mice. Complete tumor elimination was achieved in 2/8 mice, and these mice were both protected against a subsequent contralateral rechallenge and showed increased ex vivo peripheral tumor antigen-specific recall, suggesting memory T cells are induced by 2 . Signatures of M1 macrophage polarization were also evident in tumor tissue from the remaining 6/8 mice treated with 2 compared to untreated tumors. These findings demonstrate Ru(II) complexation plays a critical role in ER targeting which triggers ICD, highlighting the potential of Ru(II) agents as future in situ tumor vaccines.
Open AccessRu(II)-Photoactive Agents for Targeting ER Stress and Immunogenic Cell Death
Immunotherapy has emerged as a promising avenue for cancer treatment by bolstering the immune system’s ability to recognize and attack cancer cells. Photodynamic therapy shows potential in enhancing antitumor immunity, though the mechanisms behind its success are not fully understood. In this manuscript, we investigate two previously reported green light activated PCT/PDT agents where compound 2 - [Ru(tpy)(Me2bpy)( 3 )] 2+ , (tpy = 2,2’:6’,2’’- terpyridine, Me2bpy = 6,6’-dimethyl-2,2’-bipyridine, 3 = pyridyl-BODIPY-I2,) - shows remarkable photoselectivity in assays containing both 2D cancer cells and 3D cocultures containing BALB/c macrophages and 4T1 murine breast cancer cells. Through flow cytometry and protein analysis, we found complex 2 displays superior evidence of induced endoplasmic reticulum (ER) stress markers and indicators of immunogenic cell death (ICD) compared to its ligand 3 , despite its weaker photoselectivity. Most importantly, these results were supported by in vivo studies where 2 produced anti-tumor immunity against the 4T1 tumor model in BALB/c mice. Complete tumor elimination was achieved in 2/8 mice, and these mice were both protected against a subsequent contralateral rechallenge and showed increased ex vivo peripheral tumor antigen-specific recall, suggesting memory T cells are induced by 2 . Signatures of M1 macrophage polarization were also evident in tumor tissue from the remaining 6/8 mice treated with 2 compared to untreated tumors. These findings demonstrate Ru(II) complexation plays a critical role in ER targeting which triggers ICD, highlighting the potential of Ru(II) agents as future in situ tumor vaccines.